3-氯磺酰基苯甲酸 | 4025-64-3

• 物质功能分类: 化学试剂 - 有机试剂 - 磺酰卤化物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-氯磺酰基苯甲酸
• 中文别名: 3-(氯磺酰基)苯甲酸；3-氯磺酰苯甲酸；间羧酸苯磺酰氯；间氯磺酰基苯甲酸
• 英文名称: 3-Carboxybenzenesulfonyl chloride
• 英文别名: 3-(chlorosulfonyl)benzoic acid；3-chlorosulfonylbenzoic acid
• CAS: 4025-64-3
• 化学式: C₇H₅ClO₄S
• mdl: MFCD00024877
• 分子量: 220.633
• InChiKey: LMRKXSDOAFUINK-UHFFFAOYSA-N

物化性质

• 熔点：
  128-130 °C(lit.)
• 沸点：
  402.5±28.0 °C(Predicted)
• 密度：
  1.591±0.06 g/cm3(Predicted)
• 溶解度：
  溶于甲醇
• 稳定性/保质期：
  在常温常压下保持稳定

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  79.8
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• TSCA：
  Yes
• 危险等级：
  8
• 危险品标志：
  C
• 安全说明：
  S26,S27,S36/37/39,S45
• 危险类别码：
  R22,R34,R29
• WGK Germany：
  3
• 海关编码：
  2916399090
• 危险品运输编号：
  UN 3261 8/PG 2
• 危险类别：
  8
• 包装等级：
  II
• 危险标志：
  GHS05
• 危险性描述：
  H314
• 危险性防范说明：
  P280,P305 + P351 + P338,P310
• 储存条件：
  请将药品存放在避光、通风干燥的地方，并密封保存。

SDS

Name:	3-(Chlorosulfonyl)benzoic acid 98% (titr.) Material Safety Data Sheet
Synonym:
CAS:	4025-64-3

Section 1 - Chemical Product MSDS Name:3-(Chlorosulfonyl)benzoic acid 98% (titr.) Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
4025-64-3	3-(Chlorosulfonyl)benzoic acid	98	223-692-8

Hazard Symbols: C
Risk Phrases: 34

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Causes burns.Moisture sensitive.The toxicological properties of this material have not been fully investigated.Corrosive.
Potential Health Effects
Eye:
Causes eye burns.
Skin:
Causes skin burns.
Ingestion:
May cause severe and permanent damage to the digestive tract. Causes gastrointestinal tract burns. The toxicological properties of this substance have not been fully investigated.
Inhalation:
Causes chemical burns to the respiratory tract. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately. Do NOT allow victim to rub eyes or keep eyes closed.
Extensive irrigation with water is required (at least 30 minutes).
Skin:
Get medical aid immediately. Immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse. Destroy contaminated shoes.
Ingestion:
Do not induce vomiting. If victim is conscious and alert, give 2-4 cupfuls of milk or water. Never give anything by mouth to an unconscious person. Get medical aid immediately.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If breathing is difficult, give oxygen. Do NOT use mouth-to-mouth resuscitation. If breathing has ceased apply artificial respiration using oxygen and a suitable mechanical device such as a bag and a mask.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Clean up spills immediately, observing precautions in the Protective Equipment section. Sweep up or absorb material, then place into a suitable clean, dry, closed container for disposal. Avoid generating dusty conditions. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Minimize dust generation and accumulation. Keep container tightly closed. Do not get on skin or in eyes. Do not ingest or inhale. Discard contaminated shoes.
Storage:
Keep container closed when not in use. Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 4025-64-3: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Powder
Color: white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 137 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water: decomposes
Specific Gravity/Density:
Molecular Formula: C7H5ClO4S
Molecular Weight: 220.63

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, dust generation, moisture, strong oxidants.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, carbon monoxide, oxides of sulfur, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 4025-64-3 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
3-(Chlorosulfonyl)benzoic acid - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S.*
Hazard Class: 8
UN Number: 3261
Packing Group: III
IMO
Shipping Name: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S.
Hazard Class: 8
UN Number: 3261
Packing Group: III
RID/ADR
Shipping Name: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S.
Hazard Class: 8
UN Number: 3261
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: C
Risk Phrases:
R 34 Causes burns.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 28A After contact with skin, wash immediately with
plenty of water.
S 37 Wear suitable gloves.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 4025-64-3: No information available.
Canada
CAS# 4025-64-3 is listed on Canada's NDSL List.
CAS# 4025-64-3 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 4025-64-3 is listed on the TSCA inventory.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-氯磺酰基苯甲酸 在 ammonium hydroxide 作用下， 以 乙酸乙酯 为溶剂， 生成 间羧基苯磺酰胺
  参考文献：
  名称：

  高效选择性二肽基肽酶 4 抑制剂的设计、合成和药理学评价

  摘要：

  描述了二肽基肽酶-4 (DPP-4) 的一系列融合 β-高苯丙氨酸抑制剂的优化。对 6 的 P2 结合部分 (IC50 = 10 nM) 的修饰导致发现了含有吡咯烷-2-基甲基酰胺的 β-高苯丙氨酸衍生物。在苯环的间位引入磺胺提高了对抗 DPP-4 的效力（增加了 6-12 倍）。化合物 14k 显示出 DPP-4 抑制活性，IC50 值为 0.87 nM。同时，体内实验表明，14h 的疗效与剂量为 10 mg/kg 的西格列汀相当。

  DOI：

  10.1002/ardp.201500082
• 作为产物：
  描述：

  3-硫苯甲酸 在 五氯化磷 作用下， 生成 3-氯磺酰基苯甲酸
  参考文献：
  名称：

  Robotic system for underwater inspection of bridge piers

  摘要：

  研究目标是开发一种自动机器人系统，对桥梁下部结构进行安全、经济的水下检测。正在开发的系统概念是一种半自主机器人系统，可携带传感器平台在水下检测支撑柱的冲刷、老化或损坏情况。它向系统操作员提供位置数据和传感器信息（视频图像）；在记录这些数据和信息的同时，还可以进行口头注释。操作员可发出基本命令并将其传送给水下设备。机载微处理器控制器自动完成详细控制。主要的水下设备由两个相同的移动机器人组成，它们通过电缆和绞盘系统相互连接，沿着码头的相对表面移动。每个机器人都有橡胶履带或带夹板的轮子，并由内部电机驱动。拉紧连接两个机器人的缆绳可提供牵引力。机器人可以垂直和水平移动。每个机器人操作自己的驱动电机和缆绳绞盘，通过机器人和控制台之间的反馈，自动协调运动和缆绳张紧。多个机器人围绕一个支撑柱均匀分布，可以检测较大的结构。

  DOI：

  10.1109/5289.863909
• 作为试剂：
  描述：

  频哪酮 在 potassium tert-butylate 、 甲酸乙酯 、 sodium azide 、 3-氯磺酰基苯甲酸 、 potassium carbonate 、 potassium hydroxide 作用下， 以 四氢呋喃 、 水 、 乙腈 为溶剂， 反应 20.0h， 生成 1-diazo-3,3-dimethyl-2-butanone
  参考文献：
  名称：

  水性“无磺酰叠氮”（SAFE）重氮转移方案在较少的α-C-H酸性酮和酯中的应用

  摘要：

  抽象的 较早描述的重氮转移至CH酸性1,3-二羰基化合物（及其类似活化的同类物）的``无磺酰叠氮''（``SAFE''）方案已扩展至反应性较低的单羰基底物，以前需要单独的激活步骤。甲酰化原位，然后加入“安全鸡尾酒”的优化量的（通过混合叠氮化钠，碳酸钾，和得到米导致期望的重氮化合物的形成，这是由分离-carboxybenzenesulfonyl氯化物在水中）提取的产率中等至极好，并且在大多数情况下，无需额外纯化。 较早描述的重氮转移至CH酸性1,3-二羰基化合物（及其类似活化的同类物）的``无磺酰叠氮''（``SAFE''）方案已扩展至反应性较低的单羰基底物，以前需要单独的激活步骤。甲酰化原位，然后加入“安全鸡尾酒”的优化量的（通过混合叠氮化钠，碳酸钾，和得到米导致期望的重氮化合物的形成，这是由分离-carboxybenzenesulfonyl氯化物在水中）提取的产率中等至极好，并且在大多数情况下，无需额外纯化。

  DOI：

  10.1055/s-0039-1690613

文献信息

• Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20150231142A1

  公开（公告）日：2015-08-20

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及含有上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• Dual Pharmacophores - PDE4-Muscarinic Antagonistics
  申请人：Callahan James Francis

  公开号：US20090197871A1

  公开（公告）日：2009-08-06

  The present invention is directed to novel compounds of Formula (I), pharmaceutical compositions and their use in therapy, for example as inhibitors of phosphodiesterase type IV (PDE4) and as antagonists of muscarinic acetylcholine receptors (mAChRs), in the treatment of/and or prophylaxis of respiratory diseases, including antiinflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.

  本发明涉及式(I)的新化合物，药物组合物及其在治疗中的应用，例如作为磷酸二酯酶IV (PDE4)的抑制剂和毒蕈碱乙酰胆碱受体 (mAChRs)的拮抗剂，用于治疗和/或预防呼吸道疾病，包括抗炎症和/或过敏性疾病，如慢性阻塞性肺病 (COPD)、哮喘、鼻炎 (例如过敏性鼻炎)、特应性皮炎或银屑病。
• [EN] DUAL PHARMACOPHORES - PDE4-MUSCARINIC ANTAGONISTICS<br/>[FR] PHARMACOPHORES DUALS, ANTAGONISTES DES RÉCEPTEURS MUSCARINIQUES ET INHIBITEURS DE L'ACTIVITÉ PDE4
  申请人：GLAXO GROUP LTD

  公开号：WO2009100169A1

  公开（公告）日：2009-08-13

  The present invention is directed to novel compounds of Formula's (I) - (VI), and pharmaceutically acceptable salts thereof, pharmaceutical compositions and their use in therapy, for example as inhibitors of phosphodiesterase type IV (PDE4) and as antagonists of muscarinic acetylcholine receptors (mAChRs), in the treatment of and/or prophylaxis of respiratory diseases, including inflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.

  本发明涉及式(I) - (VI)的新化合物，以及其药学上可接受的盐、药物组合物及其在治疗中的应用，例如作为磷酸二酯酶IV (PDE4)的抑制剂和肌碱乙酰胆碱受体 (mAChRs)的拮抗剂，用于治疗和/或预防呼吸道疾病，包括炎症性和/或过敏性疾病，如慢性阻塞性肺病（COPD）、哮喘、鼻炎（例如过敏性鼻炎）、特应性皮炎或银屑病。
• 2-Benzazolyl-4-Piperazin-1-Ylsulfonylbenzenecarbohydroxamic Acids as Novel Selective Histone Deacetylase-6 Inhibitors with Antiproliferative Activity
  作者：Lei Wang、Marina Kofler、Gerald Brosch、Jelena Melesina、Wolfgang Sippl、Elisabeth D. Martinez、Johnny Easmon

  DOI：10.1371/journal.pone.0134556

  日期：——

  e ring was replaced by the isosteric heterocycles benzimidazole, benzoxazole, and benzothiazole and the position of the hydroxamic acid substituent on the phenyl ring was varied. Whereas compounds bearing a para substituted hydroxamic acid (9a-d) were active HDAC inhibitors, the meta substituted analogues (8a-d) were appreciably inactive. Compounds 9a-d selectively inhibited HDAC6 (IC50 = 0.1-1.0 μM)

  我们已经在建立的基于细胞的测定法中筛选了我们的化合物集合，该测定法测量表观遗传沉默的转基因的去阻抑，即基因座去阻抑测定。该筛选导致鉴定出4- [4-（1-（甲基苯并咪唑-2-基）哌嗪-1-基]磺酰基苯碳氧肟酸（9b）作为抑制HDAC1的活性物质。在初始结构活性关系研究中，1-甲基苯并咪唑环被等位杂环苯并咪唑，苯并恶唑和苯并噻唑取代，并且异羟肟酸取代基在苯环上的位置也有所变化。带有对位取代的异羟肟酸（9a-d）的化合物是活性HDAC抑制剂，而间位取代的类似物（8a-d）则无活性。与HDAC1（IC50 = 0）相比，化合物9a-d选择性抑制HDAC6（IC50 = 0.1-1.0μM）。而且，与患者匹配的正常细胞相比，也有选择性地抑制了肺癌细胞（9-6μM）的生长。与对照组相比，该化合物在S期诱导细胞周期停滞，而细胞凋亡的诱导则可忽略。分子模型研究发现，9a-d与HDAC6相互作用的MM-G
• [EN] CINNOLINE DERIVATIVES USEFUL AS CB-1 RECEPTOR INVERSE AGONISTS<br/>[FR] DÉRIVÉS DE CINNOLINE UTILES EN TANT QU'AGONISTES INVERSES DE RÉCEPTEURS CB-1
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2016115013A1

  公开（公告）日：2016-07-21

  The present invention is directed to cinnoline derivatives of formula (I) pharmaceutical compositions containing them and their use in the treatment of disorders and conditions mediated by the CB-1 receptor; more particularly, use in the treatment of disorders and conditions responsive to inverse agonism of the CB-1 receptor. More particularly, the compounds of the present invention are useful in the treatment of metabolic disorders.

  本发明涉及公式（I）的喹啉衍生物，含有它们的药物组合物以及它们在治疗由CB-1受体介导的疾病和症状中的应用；更具体地，在治疗对CB-1受体的反向激动作用响应的疾病和症状中的应用。更具体地说，本发明的化合物在治疗代谢性疾病中是有用的。

表征谱图